ANI Pharmaceuticals ANIP Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's deferred tax assets?
- ANI Pharmaceuticals (ANIP) reported deferred tax assets of $66.56M in Q1 2026.
- How has ANI Pharmaceuticals's deferred tax assets changed year-over-year?
- ANI Pharmaceuticals's deferred tax assets decreased by 24.8% year-over-year, from $88.49M to $66.56M.
- What is the long-term trend for ANI Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's deferred tax assets has grown at a 6.0% compound annual growth rate (CAGR), from $51.7M to $69.07M.
- What does deferred tax assets mean?
- Represents future tax benefits arising from temporary differences between the book value of assets/liabilities and their tax basis, or from carry-forward tax losses. These assets are realized when the firm generates sufficient taxable income to offset these differences. It serves as an indicator of future tax savings potential.